Biogen's Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst Pfizer poaches Roche's pharma R&D leader to fill MacKenzie's shoes as chief development officer Kaufman Hall: Hospital financials fared better across 2021 but still lag pre-pandemic numbers BD picks up Spanish developer of minimum residual disease cancer blood tests Optum: 3 (more) drugs in the pipeline payers should be watching Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig Anavex touts 'very large' phase 3 win for Rett syndrome drug—2 weeks after moving study's goalposts Komodo Health notches another major partnership as it gears up to go public Doctor groups urge Biden administration to disclose costs of federally funded clinical trials Otsuka signs on Jolly Good for $43M mental health VR deal CMS' Biogen decision could spell problems for Lilly, Roche Alzheimer's drugs, half of surveyed neurologists say Walmart teams up with Health at Scale to help its workers find the right doctor AstraZeneca runs first kidney disease focused Farxiga TV ad, getting in the homes of 37M people with this ‘silent disease’ Scipher Medicine decodes rheumatoid arthritis treatment with drug response blood test: study Takeda shunts jewel of Shire takeover to new spinoff Oak Hill Featured Story | By Fraiser Kansteiner Despite Biogen and certain Alzheimer's advocacy groups' opposition, the public seems to support the Centers for Medicare & Medicaid Services' restrictive coverage decision on controversial Alzheimer's disease drug Aduhelm. read more |
| |
|---|
|
|
| How To Take Your Imaging Trials to the Next Level with Automation Thursday, March 3, 2022 | 11:00 AM ET / 8:00 AM PT Join experts from ICON Medical Imaging and Medidata for this in-depth webinar to learn how to maximize automation on your imaging trial and discuss how automation: Improves the quality of your data for regulatory submission, creates efficiencies to accelerate your trial, and leverages integration to reduce manual steps. Register now. |
Top Stories By Kyle LaHucik Pfizer's new development leader is on the way from Roche. Replacing 35-year Pfizer veteran Rod MacKenzie, Ph.D., as chief development officer will be William Pao, M.D., Ph.D. read more By Dave Muoio Although the second calendar year of the COVID-19 pandemic was kinder to hospitals' bottom lines, ballooning expenses still have the industry playing catchup to 2019. read more By Conor Hale The medtech has bought Cytognos, developer of blood tests for tracking minimal residual disease, or the minuscule amounts of cancer cells left behind while a patient is in remission. read more By Paige Minemyer While much of the energy in the drug pipeline has centered on orphan drugs, novel therapies in more crowded markets have also been marching toward approval, according to a new report from Optum. read more By Eric Sagonowsky Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties appear ready to drop their dispute and move on. read more By Annalee Armstrong Anavex Life Science’s press release touting a phase 3 win for a Rett syndrome drug read very much like a doge meme. They claimed “very large” and “large” wins on the main and secondary endpoints. read more By Heather Landi Komodo Health has inked another big partnership, this time with the Chan Zuckerberg Initiative to enable patient advocacy organizations to access software and analytics to accelerate research into rare diseases. Komodo Health's co-founder and CEO Arif Nathoo, M.D., chatted with Fierce Healthcare about the company's growth, strategic acquisitions and plans to go public. read more By Kyle LaHucik International nonprofits and doctor groups are calling for the U.S. government to disclose the cost of federally funded clinical trials and are urging President Joe Biden to nominate a National Institutes of Health director who will ensure biopharmas reveal that R&D figure to the public. read more By Andrea Park Virtual reality and artificial intelligence technology developer Jolly Good is likely feeling very jolly indeed after being tapped by Otsuka Pharmaceutical to develop a mental health treatment program combining pharmacological and psychotherapeutic techniques. read more By Ben Adams Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s controversial Alzheimer’s drug, Aduhelm, to clinical trials only. In fact, half of those surveyed said CMS' decision would hit how they prescribe the rival drugs waiting in the wings that are also included in CMS' decision. read more By Rebecca Torrence Walmart is partnering with machine learning platform Health at Scale to connect its employees with personalized provider recommendations, aiming to leverage health data to improve outcomes. read more By Ben Adams Diabetes patients can be a target for chronic kidney disease but can also take aim back: This is the message from AstraZeneca’s new Farxiga TV ad, which is pushing the drug’s new CKD label. read more By Andrea Park Equipped with a blood test capable of predicting an individual’s response—or lack thereof—to the world’s largest drug class, Scipher Medicine is on its way to cracking the code of rheumatoid arthritis treatments. read more By Nick Paul Taylor Takeda keeps pumping out biotech spinoffs. Months after spawning HilleVax, the Japanese drugmaker has packed off another pair of midphase programs to seed a new rare disease player: Oak Hill Bio. read more |
